New patient biomarkers for BTK inhibitor–related heart toxicity
Official title: Novel patient biomarkers and mechanisms of TKI associated Cardiotoxicity
Funded at Ut Southwestern Medical Center · NIH-11402563 · Data updated 2026-11-12
This research looks at why some adults with chronic lymphocytic leukemia develop heart rhythm problems when taking BTK inhibitors and aims to find markers to predict and prevent it.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Ut Southwestern Medical Center NIH-funded |
| Lab location | 1 site (Dallas, United States) |
| Project start | August 5, 2023 |
| Project end | April 30, 2028 |
| Funding year | 2026 |
| Award (this year) | $643,846 |
| NIH project number | 5R01HL170038-04 |
| Project ID | NIH-11402563 on NIH RePORTER |
Who could benefit from this research
✓Could help
Adults with chronic lymphocytic leukemia who are treated with BTK inhibitors and are at risk for or concerned about heart side effects.
✕Less likely to help
Patients not on BTK inhibitors or without cardiovascular risk factors may not directly benefit.
What this research studies
Patients with CLL who take Bruton’s tyrosine kinase inhibitors can develop atrial fibrillation and other heart problems. This project builds on animal studies and starts a human study to identify which patients are at risk and what biological pathways drive these side effects. By analyzing biomarkers like IL-6 and IL-17 and tracking heart changes, the team hopes to map how BTK inhibitors affect the heart in people. The goal is to improve safety and guide personalized treatment choices for patients who need effective cancer therapy.
Why it matters
Potential benefit: If successful, this research could help doctors predict who will develop cardiotoxicity and tailor BTKI use to reduce risk.
How similar studies have gone: Preclinical studies and early human data suggest BTKIs can cause cardiotoxicity, but clear predictive biomarkers are not yet established.
Where this research is happening
-
Ut Southwestern Medical Center
Dallas, United States Active
Researchers
- Principal investigator: Addison, Daniel — Ut Southwestern Medical Center
- Study coordinator: Addison, Daniel
Related research
Other NIH-funded projects on the same topics.
-
Dual targeting of heart cell receptors to prevent chemotherapy heart damage
Atrial patients receiving the chemotherapy drug doxorubicin may be protected from heart damage by targeting two heart cell receptors at once.
-
Genetic clues for doxorubicin heart risk using patient-derived heart cells
A research project tests how human heart cells grown from stem cells react to a common chemotherapy to see which genetic differences may raise the risk of heart damage.
-
Targeting STK3 to protect the heart during breast cancer treatment
A new approach tests whether blocking STK3 can protect the heart from chemotherapy damage without reducing its cancer-fighting effect in breast cancer patients.
-
High-throughput 3D human heart tissue to screen drug safety
A Johns Hopkins team is creating a high-throughput, 3D human heart tissue model to test drug safety on human heart cells.
-
Precision imaging of heart damage from cancer treatment using metabolic MRI biomarkers
Researchers will use advanced MRI to find early metabolic signs of heart injury in cancer patients treated with common drugs, so doctors can protect the heart earlier.
-
PET imaging to detect heart damage from chemotherapy
This research tests a new PET imaging tracer to detect early heart muscle damage in people who have received cancer chemotherapy.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.